PCL and GFE cooperate on supply of superior Antigen SARS-CoV-2 rapid test

Seoul; Frankfurt am Main, 30. November 2020. – PCL Inc., and GFE today announced their cooperation to promote PCL’s CE-IVD certified “[COV04S] PCL COVID19 Ag Gold Saliva” rapid test in major parts of Europe. This antigen quick test facilitates the sample collection by testing directly with saliva. This approach for sampling reduces the discomfort of patients during sample collection, minimises the risk of insufficient sampling, and relieves medical personnel. Alternatively, nasopharyngeal swabs can be applied.  The test result is then available in just 10 minutes at very high sensitivity and specificity.

Without extra equipment being required for collection of saliva, processing or analysis, this straightforward lateral flow test is a great tool for professional application at point-of-care or in the laboratory. Hospitals, nursing rooms, companies, airports, or others with people suspected of COVID-19 could implement this rapid test to identify those reactive for SARS-CoV-2 antigen.

“With a production capacity of this kit at 1 million tests per week and a planned extension to exceed 4 million within the next weeks, we are well positioned for a game change in narrowing down the COVID-19 pandemic” said Soyoun Kim, Ph.D. CEO of PCL Inc. “With GFE’s experience in viral testing, we are pleased in having a competent partner for our business in Europe.“

“With the combined strengths of two fast moving companies in the in-vitro-Diagnostics field we are very much focused on providing state of the art and complementary technologies to our customers.” said Dr. Reiner Babiel, CEO at GFE. “The high quality of products and services, a reliable supply chain, and an unbiased focus on our customer’s needs are key pillars in our strategy. We are very pleased collaborating with PCL, which allows us expanding our portfolio of virus testing. Quickly identifying someone with suspected SARS-CoV-2 infection is completely in line with our diagnostic mission.”

Highly sensitive PCR tests might be applied to confirm positive or questionable results. The consequent, or if required, routine testing in appropriate settings will, particularly if applied in combination with other measures for risk reduction, contributing to fight the Corona pandemic.

GFE is a 100% subsidiary of the three German Red Cross organisations DRK Blutspendedienst West, DRK Blutspendedienst NSTOB, and Bayerisches Rotes Kreuz. The company provides NAT tests for the virus screening of millions of samples per year.

PCL, Inc., is a Global-Leading IVD (in-vitro diagnostic) company based on their own Sol-Gel Cap^Tm technology which enables a single test to detect multiple bio-markers at the same time.  Specifically, PCL, Inc. is specialized in providing a multiplex diagnostic solution for high-risk virus and has cooperated with GFE for supplying Germany Blood Bank including Bavarian Red Cross with Blood Bank Virus Serology Screening Solution.

For further information: